Venus Remedies Ltd.

NSE: VENUSREM BSE: 526953 SECTOR: Pharmaceuticals & Drugs  19k   60   4

228.55
0 0
NSE: Today, 03:53 PM

Price Summary

Today's High

₹ 233.85

Today's Low

₹ 226

52 Week High

₹ 264

52 Week Low

₹ 145.8

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

305.5 Cr.

Enterprise Value

294.21 Cr.

No. of Shares

1.34 Cr.

P/E

10.55

P/B

0.64

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  357.63

CASH

49.97 Cr.

DEBT

38.68 Cr.

Promoter Holding

41.76 %

EPS (TTM)

₹  21.67

Sales Growth

11.77%

ROE

11.72 %

ROCE

9.55%

Profit Growth

-9.74 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year11.77%
3 Year23.98%
5 Year8.91%

Profit Growth

1 Year-9.74%
3 Year56.14%
5 Year34.61%

ROE%

1 Year11.72%
3 Year8.13%
5 Year1.95%

ROCE %

1 Year9.55%
3 Year7.16%
5 Year4.55%

Debt/Equity

0.0861

Price to Cash Flow

7.47

Interest Cover Ratio

0

CFO/PAT (5 Yr. Avg.)

8.37505624283358

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2023 41.76 0
Dec 2022 41.76 0
Sep 2022 41.76 0
Jun 2022 41.76 0
Mar 2022 40.81 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 56.1435168673156% for the Past 3 years.
  • The company has shown a good revenue growth of 23.9769166322485% for the Past 3 years.
  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 35.4270660479028 days.
  • Company has a healthy liquidity position with current ratio of 3.20055656022059.
  • The company has a good cash flow management; CFO/PAT stands at 8.37505624283358.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 20.7076317581248.

 Limitations

  • Tax rate is low at -9.66208123929663.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
Net Sales 128.77 154.93 124.75 109.45 148.53
Total Expenditure 121.46 136.68 109.58 102.37 127.5
Operating Profit 7.31 18.25 15.17 7.08 21.03
Other Income 2.47 1.41 1.77 3.75 3.24
Interest 0 0 0 0 0
Depreciation 7.36 7.57 8.77 6.97 8.06
Exceptional Items 0 0 0 0 0
Profit Before Tax 2.42 12.09 8.17 3.86 16.21
Tax 0 1 0.44 1.25 8.67
Profit After Tax 2.42 11.09 7.73 2.61 7.54
Adjusted EPS (Rs) 1.81 8.29 5.78 1.95 5.64

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 355.07 301.84 320.23 514.62 575.18
Total Expenditure 311.51 267.55 277.16 467.76 506.36
Operating Profit 43.56 34.29 43.07 46.86 68.82
Other Income 1.19 4.51 3.58 17.76 8.43
Interest 35.44 25.15 13.05 12.73 0
Depreciation 32.73 32.95 31.05 34.28 32.58
Exceptional Items 0 -8.96 -8.81 23.44 0
Profit Before Tax -23.42 -28.26 -6.26 41.06 44.67
Tax 3.16 -1.15 1.96 -13.21 -4.32
Net Profit -26.58 -27.11 -8.23 54.27 48.99
Adjusted EPS (Rs.) -21.54 -21.97 -6.67 43.97 36.65

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 12.34 12.34 12.34 12.34 13.37
Total Reserves 355.65 328.61 319.91 387.84 436.05
Borrowings 136.86 116.08 72.26 47.52 38.68
Other N/C liabilities 21.03 20.66 23.77 11.29 7.27
Current liabilities 222.61 254.46 215.98 87.82 82.61
Total Liabilities 748.49 732.16 644.27 546.81 577.98
Assets
Net Block 369.93 346.89 271.47 244.2 224.67
Capital WIP 64.76 64.76 24.63 25.11 25.23
Intangible WIP 0 0 0 0 0
Investments 0.14 0.14 0.14 0.14 0.14
Loans & Advances 65.13 66.78 64.08 62.34 61.96
Other N/C Assets 0 0 0 1.29 1.57
Current Assets 248.53 253.59 283.94 213.74 264.41
Total Assets 748.49 732.16 644.27 546.81 577.98
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations -23.42 -19.3 2.55 17.62 44.67
Adjustment 64.73 59.2 40.39 21.59 24.83
Changes in Assets & Liabilities 10.27 3.75 20.37 69.69 -28.6
Tax Paid 0 0 0 0 0
Operating Cash Flow 51.58 43.65 77.75 132.34 40.9
Investing Cash Flow -11.48 -11.27 -4.64 55.98 -16.65
Financing Cash Flow -39.61 -34.74 -72.35 -161.88 -9.13
Net Cash Flow 0.49 -2.36 0.76 26.45 15.12

Corporate Actions

Investors Details

PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Promoters 40.81 41.76 41.76 41.76 41.76
sunev pharma solut... 17.21 - 17.21 17.21 17.21
sunev pahrma solut... - 17.21 - - -
pawan chaudhary 11.87 12.82 12.82 12.82 12.82
manu chaudhary 11.73 11.73 11.73 11.73 11.73
PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Investors 59.19 58.24 58.24 58.24 58.24
guttikonda vara la... 3.03 - - - -
mona laroia - - - - -
rajasekhar guttiko... 2.14 - - - -
k.b.shekar 1.39 1.63 1.71 1.81 1.93
ajay upadhyaya 1.31 1.31 1.31 - -
k.b. shekar - - - - -
ashish kacholia - - - - -
pradeep kumar jain - - - - 1.11
iepf 1.01 1.01 - - -
investor education... - - 1.01 1.01 1.01
llp 0.06 0.01 0.05 0.01 0.14

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Venus Remedies gets GMP certification from Ukraine7 Jun 2023, 12:17PM Venus Remedies informs about press release7 Jun 2023, 11:30AM Venus Remedies informs about press release1 Jun 2023, 3:04PM Venus Remedies secures marketing authorization for chemotherapy drug 'Docetaxel'1 Jun 2023, 12:58PM Venus Remedies informs about newspaper publication31 May 2023, 3:32PM Venus Remedies - Quaterly Results29 May 2023, 10:54PM Venus Remedies - Quaterly Results29 May 2023, 10:54PM Venus Remedies secures GMP certification from Kenya for all production facilities in Baddi23 May 2023, 12:27PM Venus Remedies informs about press release16 May 2023, 2:30PM Venus Remedies receives renewal of recognition for in-house R&D excellence by DSIR16 May 2023, 11:27AM Venus Remedies secures marketing authorization from UK MHRA for Cisplatin25 Apr 2023, 3:41PM Venus Remedies informs about press release 25 Apr 2023, 12:53PM Venus Remedies informs about press release6 Mar 2023, 11:44AM Venus Remedies receives GMP certification from Saudi Arabia27 Feb 2023, 10:38AM Venus Remedies informs about updates27 Feb 2023, 9:41AM Venus Remedies gets marketing approval for cancer drugs from Uzbekistan, Palestine22 Feb 2023, 3:40PM Venus Remedies informs about loss of share certificate 22 Feb 2023, 3:23PM Venus Remedies bags Great Place To Work Certified in India2 Feb 2023, 4:57PM Venus Remedies - Quaterly Results30 Jan 2023, 7:59PM Venus Remedies - Quaterly Results30 Jan 2023, 7:59PM Venus Remedies informs about closure of trading window 29 Dec 2022, 4:46PM Venus Remedies - Quaterly Results12 Nov 2022, 7:51PM Venus Remedies informs about confirmation certificate14 Oct 2022, 3:15PM Venus Remedies informs about newspaper publication1 Aug 2022, 5:09PM Venus Remedies - Quaterly Results30 Jul 2022, 7:05PM Venus Remedies - Quaterly Results30 Jul 2022, 7:05PM Venus Remedies - Quaterly Results30 Jul 2022, 7:05PM Venus Remedies informs about compliances-certificate11 Jul 2022, 4:29PM Venus Remedies informs about trading window closure1 Jul 2022, 12:26PM Venus Remedies informs about disclosure on related party transaction4 Jun 2022, 11:32AM Venus Remedies registers 9.22% increase in annual sales in FY2230 May 2022, 3:59PM Venus Remedies informs about loss of share certificate19 Apr 2022, 4:31PM Venus Remedies gets CII’s Responsible Export Organisation Certification13 Apr 2022, 6:00PM Venus Remedies informs about press release9 Mar 2022, 5:33PM Venus Remedies wins WHO GDP certification for quality services across entire supply chain9 Mar 2022, 12:59PM Venus Remedies - Quaterly Results31 Jan 2022, 7:27PM Venus Remedies - Quaterly Results31 Jan 2022, 7:27PM Venus Remedies gets nod under PLI scheme for manufacturer pharmaceutical goods9 Dec 2021, 9:57AM Venus Remedies informs about details of loss of share certificate19 Oct 2021, 5:08PM Venus Remedies informs about clarification11 Aug 2021, 12:19PM Venus Remedies launches full-fledged Consumer Healthcare division15 Jul 2021, 4:35PM Venus Remedies unveils covid protection policy12 Jul 2021, 1:14PM Venus Remedies wins legal battle against French firm for paracetamol patent18 Jun 2021, 1:25PM Venus Remedies partners with West Pharmaceutical Services to launch Cloti-Xa in India 13 Apr 2021, 1:33PM Venus Remedies informs about compliance certificate13 Apr 2021, 11:02AM Venus Remedies informs about confirmation certificate13 Apr 2021, 10:59AM Venus Remedies informs about clarification of price movement6 Jan 2021, 2:59PM

Venus Remedies Stock Price Analysis and Quick Research Report. Is Venus Remedies an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Venus Remedies and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 40.8998 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Venus Remedies has a Debt to Equity ratio of 0.0861 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Venus Remedies , the EPS growth was -16.6606403372925 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Venus Remedies has OPM of 11.9652422454845 % which is a bad sign for profitability.
     
  • ROE: Venus Remedies have a average ROE of 11.7214681541689 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Venus Remedies

X